Clinical Trials Logo

Polycystic Ovary Syndrome clinical trials

View clinical trials related to Polycystic Ovary Syndrome.

Filter by:

NCT ID: NCT06306417 Recruiting - Clinical trials for Polycystic Ovary Syndrome (PCOS)

A Randomized Controlled Trial of Acupuncture for Insulin Resistance in Patients With Polycystic Ovary Syndrome

Start date: September 28, 2023
Phase: N/A
Study type: Interventional

To determine the efficacy and safety of 2 different treatment modalities: 1) acupuncture plus lifestyle management (treatment group), 2) placebo plus lifestyle management (control group) in the treatment of insulin resistance in PCOS patients.

NCT ID: NCT06303219 Recruiting - Clinical trials for Polycystic Ovarian Syndrome

Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

To determine the comparative effects of traditional moderate intensity training and high intensity interval training on Anxiety, fatigue and Quality of Life in females with polycystic ovarian syndrome

NCT ID: NCT06302166 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

Effects of HICT and Intermittent Fasting on PCOS

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to compare the effects of High intensity circuit training, Intermittent Fasting, and their combination on PCOS morphology, Anthropometrics, clinical hyperandrogenism and body image concerns in females with PCOS. Participants will be divided into three groups who will receive High intensity circuit training, Intermittent fasting and their combination. The outcomes will be PCOS morphology, anthropometrics', clinical hyperandrogenism and body image concerns.

NCT ID: NCT06300593 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Activity of Chronic Inflammation in PCOS

Start date: January 15, 2024
Phase:
Study type: Observational

Chronic inflammation in polycystic ovary syndrome (PCOS) may be the result of dysregulation of cytokine production (due to insulin resistance, excess visceral fat and hyperandrogenemia), i.e., overproduction of pro-inflammatory factors (e.g. TNF, IL-1, IL-6) in relation to anti-inflammatory ones (IL-10). This condition may be an important link between obesity and insulin resistance, which is crucial in the etiopathogenesis of the syndrome. However, it is not known whether it results from the tendency to accumulate adipose tissue or is a feature of the syndrome itself. There is no data indicating the relationship between chronic inflammation and the severity of metabolic disorders and the value of ovarian reserve in women with various PCOS phenotypes.

NCT ID: NCT06256289 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome

Start date: March 31, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and Non-Alcoholic Fatty Liver Disease (NAFLD). The main questions it aims to answer are: - How can this technology help identify specific biomarkers for diagnosing PCOS combined with NAFLD? - What is the role of Canagliflozin in improving the safety and efficacy of treatment for PCOS and NAFLD patients? Participants, who are 50 non-diabetic women with PCOS, will undergo a series of assessments including cardiovascular metabolic indicators, liver NAFLD screening risk stratification, and insulin resistance index. They will be compared with 50 age and BMI-matched healthy controls. The participants will be randomized to receive either CANA/MET (Canagliflozin 100 mg daily plus Metformin 1000 mg twice daily) or MET (Metformin 1000 mg twice daily) for a continuous period of three months. The study will evaluate various parameters including menstrual patterns, anthropometric parameters, gonadal parameters, glucose-lipid homeostasis, liver enzyme indices, non-invasive hepatic fat changes, metabolomics, and NAFLD-related indicators.

NCT ID: NCT06227676 Completed - Clinical trials for Polycystic Ovary Syndrome

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

NUTRITION; GYN
Start date: July 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

85 percent of women of reproductive age experience consistent period cramps/menstrual pain, and 60% indicate that they do not use painkillers to relieve menstrual symptoms; there is a need for natural and non-medicative supplements to dysmenorrhea. The purpose of this clinical trial is to examine the effect of 'Cramp Bites'--classified by a mixture of natural ingredients researched to help with period pain--on women suffering from primary dysmenorrhea: this will be done through providing participants with the snack and surveying them on how it changes their period symptoms.

NCT ID: NCT06222437 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

NCT ID: NCT06206746 Recruiting - Clinical trials for Polycystic Ovary Syndrome

The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

Start date: February 15, 2024
Phase: N/A
Study type: Interventional

A Prospective, Multicenter, Randomized, Pivotal Study of the May Health System in Transvaginal Ablation of Ovarian Tissue under Ultrasound Guidance in Women with Infertility due to Polycystic Ovary Syndrome

NCT ID: NCT06204965 Recruiting - Clinical trials for Polycystic Ovary Syndrome

The Impact of Time-restricted Eating on the Outcomes Associated With Polycystic Ovary Syndrome

Start date: December 12, 2023
Phase: N/A
Study type: Interventional

Polycystic Ovary Syndrome (PCOS) is a disorder that affects approximately 10-15% of women of reproductive age. Increased activity of the hypothalamic-pituitary-ovarian (HPO) axis is considered to be one of the main factors associated with the pathogenesis of PCOS. The regulation of the activity of this axis is influenced by the following factors: insulin resistance and the activity of kisspeptins in the hypothalamus. It is suggested that intestinal dysbiosis may also play a key role in the pathogenesis of PCOS. It was noticed that the presence of bacteria producing gamma-aminobutyric acid in the intestine is positively correlated with the concentration of luteinizing hormone (LH) in the serum, which indicates the relationship between the functioning of the gut-brain axis and PCOS. A dysbiotic factor is an incorrect diet and inappropriate timing of its consumption, which may also lead to inhibition of kisspeptin expression in the hypothalamus and cause menstrual disorders. Due to the fact that most obese women with PCOS eat significantly more meals in the second part of the day, and these meals are characterized by a significant supply of fat and simple sugars, intestinal dysbiosis seems to be an important cause of the observed disorders, while the use of chrononutrition, consisting in synchronizing meal times with endogenous 24-hour circadian rhythms may partially restore eubiosis in the intestine and improve the reproductive, metabolic and neurohormonal health of women with PCOS. Time-restricted feeding (TRF), which involves eating food usually within 8 hours followed by 16 hours of fasting, seems to be a regime that allows restoring eubiosis in the intestinal microbiota and improving the quality of life of women with PCOS. So far, only one study has been conducted among women with PCOS who used TRF for 5 weeks and a number of positive changes were demonstrated (hormonal or metabolic). However, this study did not include an assessment of the microbial and neurohormonal parameters, which seems to be a key issue. Taking the above into account, it was hypothesized that TRF may be an appropriate therapeutic tool for women with PCOS, which will positively affect metabolic and hormonal parameters by changing the composition of the intestinal microbiota. Therefore, the main aim of the experiment is to investigate the impact of TRF on the composition of the intestinal microbiota, its metabolites, and metabolic and neurohormonal parameters in women with PCOS.

NCT ID: NCT06199544 Recruiting - Comparative Study Clinical Trials

Effect of Unani Medicine for the Management of Anomalies Associated With Polycystic Ovarian Syndrome

Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

Currently available medications for PCOS are symptom(s) oriented but have limitations because of its complex pathophysiology. The most preferred drug against PCOS is metformin which act as an insulin sensitizer to improve insulin-glucose metabolism and anovulatory cycles in PCOS. However, its use is associated with various side effects such as bloating, diarrhea and nausea. Thus, it is imperative to explore various other alternatives to combat this gynecological problem.